Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Surgical Oncology ClinicsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
Soft tissue and bone tumors, WHO classification of tumours, 5th edition. vol. 3: Lyon, France: IARC; 2020.
- Identification of novel genes, SYT and SSX, involved in the t(X;18)(p11.2;q11.2) translocation found in human synovial sarcoma.Nat Genet. 1994; 7: 502-508
- Rearrangement of the transcription factor gene CHOP in myxoid liposarcomas with t(12;16)(q13;p11).Genes Chromosomes Cancer. 1992; 5: 278-285
- Fusion of the EWS and CHOP genes in myxoid liposarcoma.Oncogene. 1996; 12: 489-494
- Age as an independent prognostic factor for survival of localised synovial sarcoma patients.Br J Cancer. 2015; 113: 1602-1606
- Synovial Sarcoma: Current Concepts and Future Perspectives.J Clin Oncol. 2018; 36: 180-187
- Systemic Treatment for Adults with Synovial Sarcoma.Curr Treat Options Oncol. 2018; 19: 13
- Dose Reduction of Preoperative Radiotherapy in Myxoid Liposarcoma: A Nonrandomized Controlled Trial.JAMA Oncol. 2021; 7: e205865
- Volume changes in soft tissue sarcomas during preoperative radiotherapy of extremities evaluated using cone-beam CT.J Radiat Oncol. 2013; 2: 55-62
- Radiosensitivity translates into excellent local control in extremity myxoid liposarcoma: a comparison with other soft tissue sarcomas.Cancer. 2009; 115: 3254-3261
- Irradiation of myxoid/round cell liposarcoma induces volume reduction and lipoma-like morphology.Acta Oncol. 2007; 46: 838-845
- Radiation response: an additional unique signature of myxoid liposarcoma.Int J Radiat Oncol Biol Phys. 2004; 60: 522-526
- Time Trends and Prognostic Factors for Overall Survival in Myxoid Liposarcomas: A Population-Based Study.Sarcoma. 2020; 2020: 2437850
- Myxoid∖round cell liposarcoma (MRCLS) revisited: an analysis of 418 primarily managed cases.Ann Surg Oncol. 2012; 19: 1081-1088
- Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial.Lancet. 2002; 359: 2235-2241
- Patterns of Perioperative Treatment and Survival of Localized, Resected, Intermediate- or High-Grade Soft Tissue Sarcoma: A 2000-2017 Netherlands Cancer Registry Database Analysis.Sarcoma. 2021; 2021: 9976122
- Effectiveness of radiotherapy in myxoid sarcomas is associated with a dense vascular pattern.Int J Radiat Oncol Biol Phys. 2008; 72: 1480-1487
- Efficacy of neoadjuvant hypofractionated radiotherapy in patients with locally advanced myxoid liposarcoma.Eur J Surg Oncol. 2016; 42: 891-898
- Trabectedin and RAdiotherapy in Soft Tissue Sarcoma (TRASTS): Results of a Phase I Study in Myxoid Liposarcoma from Spanish (GEIS), Italian (ISG), French (FSG) Sarcoma Groups.EClinicalMedicine. 2019; 9: 35-43
- Assessment of Safety and Efficacy of Combined Trabectedin and Low-Dose Radiotherapy for Patients With Metastatic Soft-Tissue Sarcomas: A Nonrandomized Phase 1/2 Clinical Trial.JAMA Oncol. 2020; 6: 535-541
- Cellular Radiosensitivity of Soft Tissue Sarcoma.Radiat Res. 2021; 196: 23-30
- Radiotherapy is Associated With Improved Survival in Patients With Synovial Sarcoma Undergoing Surgery: A National Cancer Database Analysis.J Surg Res. 2020; 255: 378-387
- Perioperative radiotherapy is associated with improved survival among patients with synovial sarcoma: A SEER analysis.J Surg Oncol. 2015; 111: 158-164
- Effects of Adjuvant Radiotherapy in Patients With Synovial Sarcoma.Am J Clin Oncol. 2017; 40: 306-311
- Long-term outcomes for synovial sarcoma treated with conservation surgery and radiotherapy.Int J Radiat Oncol Biol Phys. 2007; 69: 1173-1180
- A prediction model for treatment decisions in high-grade extremity soft-tissue sarcomas: Personalised sarcoma care (PERSARC).Eur J Cancer. 2017; 83: 313-323
- Development and external validation of two nomograms to predict overall survival and occurrence of distant metastases in adults after surgical resection of localised soft-tissue sarcomas of the extremities: a retrospective analysis.Lancet Oncol. 2016; 17: 671-680
- Development and external validation of a dynamic prognostic nomogram for primary extremity soft tissue sarcoma survivors.EClinicalMedicine. 2019; 17: 100215
- Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial.Lancet Oncol. 2012; 13: 1045-1054
- Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial.J Clin Oncol. 2001; 19: 1238-1247
- Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial.Lancet Oncol. 2017; 18: 812-822
- Short, full-dose adjuvant chemotherapy in high-risk adult soft tissue sarcomas: a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group.J Clin Oncol. 2012; 30: 850-856
- Neoadjuvant Chemotherapy in High-Risk Soft Tissue Sarcomas: Final Results of a Randomized Trial From Italian (ISG), Spanish (GEIS), French (FSG), and Polish (PSG) Sarcoma Groups.J Clin Oncol. 2020; 38: 2178-2186
- Effect of high-dose ifosfamide in advanced soft tissue sarcomas. A multicentre phase II study of the EORTC Soft Tissue and Bone Sarcoma Group.Eur J Cancer. 2000; 36: 61-67
- Effect of Neoadjuvant Chemotherapy Plus Regional Hyperthermia on Long-term Outcomes Among Patients With Localized High-Risk Soft Tissue Sarcoma: The EORTC 62961-ESHO 95 Randomized Clinical Trial.JAMA Oncol. 2018; 4: 483-492
- Advanced soft-tissue sarcoma: a disease that is potentially curable for a subset of patients treated with chemotherapy.Eur J Cancer. 2003; 39: 64-69
- Trends in survival for patients with metastatic soft-tissue sarcoma.Cancer. 2011; 117: 1049-1054
- Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas: The ANNOUNCE Randomized Clinical Trial.JAMA. 2020; 323: 1266-1276
- Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up.Ann Oncol. 2021; 32: 1348-1365
- Staging and Surveillance of Myxoid Liposarcoma: Follow-up Assessment and the Metastatic Pattern of 169 Patients Suggests Inadequacy of Current Practice Standards.Ann Surg Oncol. 2021; 28: 7903-7911
- Stereotactic body radiation therapy for lung metastases from soft tissue sarcoma.Eur J Cancer. 2015; 51: 668-674
- Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.Lancet Oncol. 2014; 15: 415-423
- Efficacy of first-line doxorubicin and ifosfamide in myxoid liposarcoma.Clin Sarcoma Res. 2012; 2: 2
- Prognostic factors in advanced synovial sarcoma: an analysis of 104 patients treated at the Royal Marsden Hospital.Ann Oncol. 2005; 16: 437-444
- Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG).Eur J Cancer. 2010; 46: 72-83
- Synovial Sarcoma in Children, Adolescents, and Young Adults: A Report From the Children's Oncology Group ARST0332 Study.J Clin Oncol. 2021; 39: 3927-3937
- Synovial sarcoma. Uniform response of metastases to high dose ifosfamide.Cancer. 1994; 73: 2506-2511
- Clinical activity and tolerability of a 14-day infusional Ifosfamide schedule in soft-tissue sarcoma.Sarcoma. 2013; 2013: 868973
- Phase II trial of first-line high-dose ifosfamide in advanced soft tissue sarcomas of the adult: a study of the Spanish Group for Research on Sarcomas (GEIS).Ann Oncol. 1998; 9: 871-876
- Successful Ifosfamide Rechallenge in Soft-Tissue Sarcoma.Am J Clin Oncol. 2018; 41: 147-151
- High-dose ifosfamide as second- or third-line chemotherapy in refractory bone and soft tissue sarcoma patients.Oncology. 2011; 80: 257-261
- High-dose ifosfamide: circumvention of resistance to standard-dose ifosfamide in advanced soft tissue sarcomas.J Clin Oncol. 1995; 13: 1600-1608
- High-Dose Ifosfamide Chemotherapy in a Series of Patients Affected by Myxoid Liposarcoma.Sarcoma. 2017; 2017: 3739159
- Mode of action of trabectedin in myxoid liposarcomas.Oncogene. 2014; 33: 5201-5210
- Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study.Lancet Oncol. 2007; 8: 595-602
- Trabectedin in advanced synovial sarcomas: a multicenter retrospective study from four European institutions and the Italian Rare Cancer Network.Anticancer Drugs. 2015; 26: 678-681
- Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial.Lancet. 2012; 379: 1879-1886
- Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043).J Clin Oncol. 2009; 27: 3126-3132
- Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial.Lancet Oncol. 2016; 17: 1732-1742
- Safety and Efficacy of Anlotinib, a Multikinase Angiogenesis Inhibitor, in Patients with Refractory Metastatic Soft-Tissue Sarcoma.Clin Cancer Res. 2018; 24: 5233-5238
- The Efficacy and Safety of Apatinib in Advanced Synovial Sarcoma: A Case Series of Twenty-One Patients in One Single Institution.Cancer Manag Res. 2020; 12: 5255-5264
- Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial.Lancet. 2016; 387: 1629-1637
- Activity of Eribulin in Patients With Advanced Liposarcoma Demonstrated in a Subgroup Analysis From a Randomized Phase III Study of Eribulin Versus Dacarbazine.J Clin Oncol. 2017; 35: 3433-3439
- Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial.Lancet Oncol. 2017; 18: 1397-1410
- Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected].J Clin Oncol. 2007; 25: 2755-2763
- Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas study.J Clin Oncol. 2011; 29: 2528-2533
- Epigenetic Targets in Synovial Sarcoma: A Mini-Review.Front Oncol. 2019; 9: 1078
- Preclinical Evidence of Anti-Tumor Activity Induced by EZH2 Inhibition in Human Models of Synovial Sarcoma.PLoS One. 2016; 11e0158888
- Phase 2 multicenter study of the EZH2 inhibitor tazemetostat in adults with synovial sarcoma.J Clin Oncol. 2017; 35: 1057-11057
NCT04965753. 2022. Available at: https://clinicaltrials.gov/ct2/show/NCT04965753. Accessed February 17, 2022.
- NY-ESO-1 (CTAG1B) expression in mesenchymal tumors.Mod Pathol. 2015; 28: 587-595
- Monophasic and biphasic synovial sarcomas abundantly express cancer/testis antigen NY-ESO-1 but not MAGE-A1 or CT7.Int J Cancer. 2001; 94: 252-256
- The cancer-testis antigen NY-ESO-1 is highly expressed in myxoid and round cell subset of liposarcomas.Mod Pathol. 2013; 26: 282-288
- NY-ESO-1 is a ubiquitous immunotherapeutic target antigen for patients with myxoid/round cell liposarcoma.Cancer. 2012; 118: 4564-4570
- Immunohistochemical expression and clinicopathological assessment of the cancer testis antigens NY-ESO-1 and MAGE-A4 in high-grade soft-tissue sarcoma.Oncol Lett. 2019; 17: 3937-3943
- Cancer-testis antigen expression in synovial sarcoma: NY-ESO-1, PRAME, MAGEA4, and MAGEA1.Hum Pathol. 2017; 61: 130-139
- Antitumor Activity Associated with Prolonged Persistence of Adoptively Transferred NY-ESO-1 (c259)T Cells in Synovial Sarcoma.Cancer Discov. 2018; 8: 944-957
- Targeting cancer testis antigens in synovial sarcoma.J Immunother Cancer. 2021; 9: e002072
- Facts and Hopes in Immunotherapy of Soft-Tissue Sarcomas.Clin Cancer Res. 2020; 26: 5801-5808
Article info
Identification
Copyright
© 2022 Elsevier Inc. All rights reserved.
